

# ESMO Advanced Course on Perioperative Strategies in Localized Malignancies: State of the Art and Future Directions in Lung Cancer

**PROGRAMME**

**ESMO  
ADVANCED COURSE**

**HONG KONG SAR CHINA  
20-21 APRIL 2024**

**Co-Chairs**

Rafal Dziadziuszko, Poland

Tony S. K. Mok, Hong Kong SAR, China

Fan Yang, China

# ESMO ADVANCED COURSE PROGRAMME

## PERIOPERATIVE STRATEGIES IN LOCALIZED MALIGNANCIES

State of the art and future directions in lung cancer

Hong Kong SAR, China  
20-21 April 2024

---

### CO-CHAIRS

Rafal Dziadziuszko, Poland  
Tony S. K. Mok, Hong Kong SAR, China  
Fan Yang, China

### SPEAKERS

Hisao Asamura, Japan  
Thanyanan Baisamut (Reungwetwattana), Thailand  
Rina Hui, Hong Kong SAR, China  
Rainbow W. H. Lau, Hong Kong SAR, China  
Natasha Leighl, Canada  
Molly S. C. Li, Hong Kong SAR, China  
Alan D. L. Sihoe, Hong Kong SAR, China  
Pan-Chyr Yang, Taiwan  
Yi-Long Wu, China

---

### LEARNING OBJECTIVES

- To update the importance of early lung detection in smokers and never-smokers
- To appreciate the implication of latest staging and molecular classification for early-stage lung cancer
- To learn the advances in surgical management of early-stage lung cancer
- To comprehend the role of neo-adjuvant and adjuvant therapy for patients with oncogene-driven and non-oncogene-driven resectable lung cancer

---

### ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Saturday, 20 April 2024

---

- 09:00-09:10 **Welcome and introduction**  
Rafal Dziadziuszko, PL  
Tony S. K. Mok, HK SAR, CN  
Fan Yang, CN
- 09:10-10:15 **Session 1 – Screening, staging and molecular testing**  
**Chair: Tony S. K. Mok, HK SAR, CN**
- 15' Screening (Asia perspective)  
Pan-Chyr Yang, TW
- 15' Screening (EU perspective)  
Rafal Dziadziuszko, PL
- 20' Staging  
Hisao Asamura, JP
- 15' Discussion
- 10:15-10:45 Coffee break**
- 10:45-12:00 **Session 2 – Surgery**  
**Chair: Rafal Dziadziuszko, PL**
- 20' Current surgical approach to lung cancer: Segmentectomic vs lobectomy  
Alan D. L. Sihoe, HK SAR, CN
- 20' Resection of the marginally resectable lung cancer  
Fan Yang, CN
- 20' Advances in surgical techniques  
Rainbow W. H. Lau, HK SAR, CN
- 15' Discussion
- 12:00-12:55 **Session 3 – Neo-adjuvant, adjuvant and targeted therapies – Part I**  
**Chair: Rafal Dziadziuszko, PL**
- 20' Neo-adjuvant vs adjuvant (focusing on non-oncogene)  
Molly S. C. Li, HK SAR, CN
- 20' Do biomarkers and MRD matter? (PDL1, TMB, ...)  
Tony S. K. Mok, HK SAR, CN
- 15' Discussion
- 12:55-14:00 Lunch**
- 14:00-14:55 **Session 4 – Early stage, oncogene**  
**Chair: Tony S. K. Mok, HK SAR, CN**
- 20' Early resectable lung cancer  
Yi-Long Wu, CN
- 20' Basic management of stage III  
Rafal Dziadziuszko, PL
- 15' Discussion
- 14:55-15:30 Coffee break**

- 15:30-16:50 **Session 5 – Management of stage III non-oncogene driven lung cancer**  
**Chair: Tony S. K. Mok, HK SAR, CN**
- 25' Standard of radiation therapy  
Rafal Dziadziuszko, PL
- 20' Should we give I/O to all stage III patients after concurrent chemoradiation?  
Rina Hui, HK SAR, CN
- 20' The philosophy of multidisciplinary approach to management of stage III disease  
Thanyanan Baisamut (Reungwetwattana), TH
- 15' Discussion and closure of the day
- 19:00      *Networking dinner***

## Sunday, 21 April 2024

---

- 09:00-09:30 **Session 6 – Neo-adjuvant, adjuvant and targeted therapies – Part II**  
**Chair: Rafal Dziadziuszko, PL**
- 25' Molecular testing for operable lung cancer: When, who and how?  
Natasha Leighl, CA
- 5' Discussion
- 09:30-13:00 **Workshop sessions**
- 25' Introduction based on clinical cases presented by speakers  
35' Discussion
- Workshop 1**  
60' **MTB: Multiple GGO and very early NSCLC**  
Speaker: Rainbow W. H. Lau, HK SAR, CN  
Moderator: Fan Yang, CN
- 10:30-11:00      *Coffee break***
- Workshop 2**  
60' **MTB: Stage II and stage III EGFR mutation positive**  
Speaker: Natasha Leighl, CA  
Moderator: Tony S. K. Mok, HK SAR, CN
- Workshop 3**  
60' **MTB: T4 / N2 disease**  
Speaker: Molly S. C. Li, HK SAR, CN  
Moderator: Rafal Dziadziuszko, PL
- 13:00-13:15 **Synthesis and conclusion**  
Rafal Dziadziuszko, PL  
Tony S. K. Mok, HK SAR CN  
Fan Yang, CN
- 13:15-14:15      *Lunch***